Rewind Therapeutics
Pioneering novel treatments for neurological diseases, advancing the way to effective remyelination for multiple sclerosis and myelin-related conditions.
Pioneering novel treatments for neurological diseases, advancing the way to effective remyelination for multiple sclerosis and myelin-related conditions.
Rewind Therapeutics is a biotechnology startup founded in 2017, dedicated to pioneering novel treatments for neurological diseases. The company's innovative approach focuses on advancing the way to effective remyelination for multiple sclerosis and myelin-related conditions. By employing first-in-class remyelinating therapeutics, Rewind Therapeutics inhibits signals that restrict the expansion and migration of oligodendrocyte stem cells, thus promoting effective remyelination. This breakthrough technology offers a promising avenue for medical practitioners to more efficiently treat patients suffering from multiple sclerosis and other myelin-related diseases. The company's recent Series A investment at 25 January 2023 drew attention from a diverse group of investors including Sunstone Capital, MERL Ventures Fund, PMV, Gemma Frisius Fund, Centre for Drug Design & Discovery (CD3), Boehringer Ingelheim Venture Fund. With its focus on disrupting the biotechnology and health and wellness industries, Rewind Therapeutics shows significant potential for addressing critical unmet medical needs.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | Unknown | 6 |
|
25 Jan 2023 |
| Grant | €2.90M | 1 | Agentschap Innoveren & Ondernemen | 01 Aug 2019 |
| Series A | €15.20M | 3 |
|
04 Jan 2018 |
No recent news or press coverage available for Rewind Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
